Overview

Update
Status
Acquired by on April 10, 2012
Total Equity Funding
$52M in 2 Rounds from 7 Investors
Headquarters:
South San Francisco, CA
Description:
KAI Pharmaceuticals discovers and develops novel therapeutics for cardiovascular diseases, kidney diseases and pain.
Founders:
,
Categories:
Therapeutics, Biotechnology, Medical
Website:
http://www.kaipharmaceuticals.com
Social:

Company Details

Update

KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI second core program, KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients, is expected to enter human clinical trials in 2010. KAI also has an ongoing pain program, KAI-1678, which is currently in Phase 2a testing.

Funding Rounds (2) - $52M

Update
DateAmount / RoundValuationLead InvestorInvestors
May, 2006$35M / Series B7
Dec, 2003$17M / Series A4

Current Team (1)

Update
  • Founder / CSO / Scientific Consultant / Chairperson, Scientific Advisory Board Director

Board Members and Advisors (3)

Update

Offices/Locations (1)

Update
  • Office

    270 Littlefield Avenue

    South San Francisco, CA 94080

    USA

Past Team (4)

Update

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos